Tak Paul Peter 4
4 · Candel Therapeutics, Inc. · Filed Nov 21, 2024
Insider Transaction Report
Form 4
Tak Paul Peter
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2024-11-21$1.55/sh+12,900$19,995→ 343,635 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-11-21−12,900→ 1,763,968 totalExercise: $1.55Exp: 2030-10-10→ Common Stock (12,900 underlying)
Footnotes (1)
- [F1]25% of this option vested and became exercisable on October 10, 2020, with another 25% vesting on October 10, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.